Search

Displaying results 571 - 580 of 10000 in total
  1. Drug

    Minoxidil

    go.drugbank.com/drugs/DB00350
    ApprovedInvestigational

    A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

    Mixtures: FluMisch 5% Minoxidil, Bakumokon 5% MinoxidilProducts: MINOXIDIL 10 MG TABLETAS, MİNOX F5 % 5 ÇÖZELTİ KÖPÜK, 100 ML
  2. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

    Products: TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET
  3. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). … The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335]

    Products: MABCAMPATH INF SOL ICIN 30 MG/ML KONS 1 ML 3 FLK (10 MG/ML KONSANTRE 3 AMP), MABCAMPATH ® 30 MG/ML
  4. Drug

    Laurus nobilis

    go.drugbank.com/drugs/DB10670
    Approved

    Laurus nobilis allergenic extract is used in allergenic testing.

    Synonyms: bay leaf allergenic extractProducts: Bay Leaf
  5. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]

    Mixtures: PICOPREP 10 MG / 3,5 G /12 G ORAL ÇÖZELTI IÇIN TOZ, 2 SAŞE, CITRAFLEET 0.01 G/ 3.50 G/ 10.97 G ORAL ÇÖZELTI HAZIRLAMAK IÇIN TOZ IÇEREN SAŞE , 2 ADETProducts: Laxapico 2,5 mg Yumuşak Kapsül, 50 adet, DULCOLAX 2.5 MG YUMUSAK JELATIN KAPSUL, 50 ADET
  6. Drug

    Cetirizine

    go.drugbank.com/drugs/DB00341
    ApprovedInvestigational

    Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal … The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms.

    Mixtures: ACERADOX® GProducts: CETRYN 5 MG/5 ML SURUP, 100 ML, YENIZIN 5 MG/5 ML ŞURUP, 100 ML
  7. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg. … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.

    Mixtures: TELEBRIX 35 FLAKON, 100 ML, TELEBRIX 35 FLAKON, 100 MLProducts: TELEBRIX 30 MEGLUMIN FLAKON, 100 ML, TELEBRIX 35 FLAKON, 50 ML
  8. Drug

    Vespula vulgaris venom protein

    go.drugbank.com/drugs/DB11033
    Approved

    Vespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.

    Mixtures: Mixed Vespid Venom Protein Multidose 13.0 Ml (3900 Mcg), Hymenoptera Venom Product-mixed Vespid Venom Protein (1650 Mcg)Products: ALUTARD SQ Wespengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml), Yellow Jacket Venom Protein Multidose 13.0 Ml (1300 Mcg)
  9. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    [L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]

    Mixtures: VESOMNİ 6 MG/0.4 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 ADET, Vesomni 6 mg/0,4 mg Tabletten mit veränderter WirkstofffreisetzungCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  10. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    [A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: MESTINON TABLET 10 mg, MİYASTU 180 MG UZATILMIŞ SALIMLI TABLET, 30 ADET